
Tvardi Therapeutics fell 74.9% from $4.03 to $1.01, behind the S&P 500's +10.0%. Its worst day was Jun 26 (−36.4%), and its low came Oct 30 at $0.79.
Nov 17, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.78 missed the $-0.56 estimate on $0.00 revenue.
−5.7% · S&P 500 +0.8%
EPS of $-0.73 missed the $-0.70 estimate on $0.00 revenue.
Story events cover the past 12 months · Times ET
−0.7% · S&P 500 +0.8%
Tvardi Therapeutics shares fell 36.4%, while the S&P 500 fell 0.7%.
−36.4%, the year's worst day · S&P 500 −0.7%
Tvardi Therapeutics closed at its highest level of the year, 24.1% above where the year started.
+61.3%, the year's best day · S&P 500 −0.3%
EPS of $-0.69 missed the $-0.64 estimate on $0.00 revenue.
+7.3% · S&P 500 −0.2%
Tvardi Therapeutics closed at its lowest level of the year, 80.3% below where the year started.
−8.1% · S&P 500 −1.8%
EPS of $-0.48 beat the $-0.56 estimate on $0.00 revenue.
+2.2% · S&P 500 −0.4%
Where it ended: a close of $1.01 on Nov 17, 2026.
Nothing in the past 12 months.
All TVRD dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for TVRD and SPY from Benzinga historical bars. Not investment advice.